Actively Recruiting
Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator
Led by University of Rochester · Updated on 2025-09-18
2000
Participants Needed
13
Research Sites
4 weeks
Total Duration
On this page
Sponsors
U
University of Rochester
Lead Sponsor
P
Patient-Centered Outcomes Research Institute
Collaborating Sponsor
AI-Summary
What this Trial Is About
This trial investigates the comparative effectiveness of two beta-blocker drugs, carvedilol and metoprolol succinate, in adults with heart failure with reduced ejection fraction HFrEF who have an implantable cardioverter defibrillator ICD. The study aims to provide clear data on which medication better reduces the risk of ICD therapy, cardiovascular hospitalizations, or cardiovascular death. It is a prospective, multicenter, randomized clinical trial enrolling 2,000 participants across 100 U.S. sites, including an 18-month feasibility phase. Participants currently taking metoprolol succinate will be randomized to either continue this treatment or switch to carvedilol at an equivalent dose. Both groups will have their doses adjusted to the maximum tolerated level as per the study protocol. The feasibility phase will evaluate recruitment, safety, adherence, and retention, while the full study will follow participants for up to three years, assessing clinical outcomes and quality of life. During the study, participants will undergo regular assessments including ICD device checks, laboratory tests, imaging, and surveys on quality of life and anxiety related to ICD shocks. Data collected will include cardiovascular events, healthcare use, medication adherence, and patient-reported outcomes measured at baseline and throughout the follow-up. The trial will also analyze results by patient subgroups such as age, sex, race, heart failure type, and ICD type to better understand treatment responses.
CONDITIONS
Brief Title
Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Implantable cardioverter defibrillator (ICD) implanted for primary prevention of HFrEF (ischemic or non-ischemic)
- Currently treated with metoprolol succinate and willing to switch to carvedilol
- Left ventricular ejection fraction (LVEF) less than 50% within the past 12 months
You will not qualify if you...
- Unwilling or unable to follow the study protocol
- Treatment with any beta-blocker other than metoprolol succinate or no beta-blocker treatment
- Known intolerance or contraindication to carvedilol
- Systolic blood pressure below 100 mmHg
- Enrollment in another clinical trial
- Inability or unwillingness to provide consent
Research Team
M
Mehmet Aktas, M.D.
N
Nicole Guerrero, MBA
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here